Annual Meeting Education Industry Supported Symposia

0414-annual-meeting-on-Womens-cancer

Annual Meeting > Industry Supported Symposia

Industry Supported Symposia

Industry Supported Symposia (ISS) are unique forums for presenting educational information to Annual Meeting attendees, free of charge. Symposia sessions are scheduled during lunch time, allowing participants the opportunity for education and networking.

ISS I: Dissecting the Decision: Investigators Discuss Available and Emerging Data Shaping the Management of Common Gynecologic Cancers
ISS II: Recent Developments in Recurrent Ovarian Cancer
ISS III: PARP Inhibition in Ovarian Cancer: Integrating the Science, the Clinical Data, and the Patient Voice to Enhance Care
ISS IV: Hereditary OvCa Cancer Testing: A Panel Discussion on Improving Outcomes
ISS V: Existing and Emerging Strategies in the Management of Patients with Uterine Sarcomas
ISS VI: Dissecting the Decision: Investigators Discuss Available and Emerging Data Shaping the Role of PARP Inhibition in the Management of Ovarian Cancer
ISS VII: Advancing Molecular Diagnostics for Gynecologic Cancer: Efforts in Data Sharing and Tumor Testing to Improve Care

ISS I: Dissecting the Decision: Investigators Discuss Available and Emerging Data Shaping the Management of Common Gynecologic Cancers

Sunday, March 12
6:30 a.m. – 7:30 a.m.
Maryland AC
(Part 1 of a 2-Part Series)
CME: 1.0 AMA PRA Category 1 Credit™ provided by Research To Practice.

Course Director:
Neil Love, MD, Research to Practice

Faculty:
Michael Birrer, MD, PhD, Harvard Medical School, Boston, MA
Angeles Alvarez-Secord, MD, Duke University Medical Center, Durham, NC
Bradley J Monk, MD, University of Arizona Cancer Center, Phoenix, AZ

The symposium will focus on the discussion of actual patients with ovarian, cervical or endometrial cancer treated within the practices of the clinical investigator faculty members. By structuring the program around real patients, Research to Practice aims to create a dynamic educational offering designed to improve clinicians’ knowledge and assist them in becoming better and more effective caregivers. During each of the live event’s topic modules, one of the faculty will deliver a brief presentation reviewing recent findings, current management approaches and ongoing research that informs their decision making of the specific disease state and/or clinical scenario(s).

Registration:
To register or learn more visit: www.ResearchToPractice.com/Meetings/GynOnc2017 

This activity is supported by Genentech and Immunogen.

ISS II: Recent Developments in Recurrent Ovarian Cancer

Sunday, March 12
12:15 p.m. – 1:45 p.m.
Maryland AC

Faculty:
Cheryl Saenz, MD, University of California, San Diego, San Diego, CA
John Chan, MD, University of California, San Francisco, San Francisco, CA
Maurie Markman, MD, Cancer Treatment Centers of America, Philadelphia, PA

The distinguished panel will provide a historical perspective on the importance of anti-angiogenesis and hold a case-based discussion on the clinical development of anti-VEGF therapy in the treatment of platinum-sensitive and platinum-resistant recurrent ovarian cancer.

This activity is supported by Genentech.

ISS III: PARP Inhibition in Ovarian Cancer: Integrating the Science, the Clinical Data, and the Patient Voice to Enhance Care

Sunday, March 12
12:15 p.m. – 1:45 p.m.
Maryland BD

Course Director:
Robert Coleman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty:
Thomas Herzog, MD, University of Cincinnati Cancer Institute, Cincinnati, OH
Ursula Matulonis MD, Dana-Farber Cancer Institute, Boston, MA
Shannon Westin, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX

Because of the volume of research regarding the use of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with recurrent ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical, in the context of shared decision making. Clinicians need expert guidance to use existing PARP inhibitors and companion diagnostics safely and effectively and to plan for optimal integration of new ones when they become available. This session will evaluate novel approaches to the treatment of patients with ovarian cancer, providing expert interpretation of emerging data and guidance regarding its application in practice in the context of shared decision making.

This activity is supported by AstraZeneca, Clovis Oncology, Myriad Genetic Laboratories, Inc., and Tesaro, Inc.

ISS IV: Hereditary Ovarian Cancer Testing: A Panel Discussion on Improving
Outcomes

Monday, March 13
12:00 p.m. – 1:30 p.m.
Maryland BD

Course Directors:
Jubilee Brown, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Beth Karlan, MD, Cedars-Sinai Medical Center, Los Angeles, CA

Speaker:
Caroline Danforth, patient advocate

The primary goal of this symposium is to provide attending clinicians an updated overview on SGO’s Clinical Practice Statement and current recommendations concerning genetic testing for ovarian cancer. This interactive program will include clinical overviews provided by the faculty as well as an opportunity for attendees to share with the panel and colleagues a better understanding of the barriers to hereditary cancer testing in their ovarian cancer patient population.

This activity is supported by Invitae.

ISS V: Existing and Emerging Strategies in the Management of Patients with Uterine Sarcomas

Tuesday, March 14
6:30 a.m. – 7:30 a.m.
Maryland AC
CME: 1.0 AMA PRA Category 1 Credit™ provided by Research To Practice.

Course Director:
Neil Love, MD, Research to Practice

Faculty:
Brian Van Tine, MD, PhD, Washington University School of Medicine, Saint Louis, MO
Suzanne George, MD, Dana-Farber Cancer Institute, Boston, MA
David Scott Miller, MD, FACOG, FACS, University of Texas Southwestern Medical Center, Dallas, TX

This symposium will focus exclusively on the diagnosis and treatment of patients with uterine sarcomas. Three leading uterine sarcoma investigators will serve as the faculty, and each will be responsible for presenting a number of challenging cases of patients previously or currently under their care. These case presentations, including any relevant radiologic or pathologic imagery, will be used to frame the agenda for the live event. The program will be divided into three distinct topic modules, each featuring a blend of moderated case-based discussion and a faculty member-led presentation of relevant data and/or ongoing clinical trials related to the clinical scenario under review. Clinicians in attendance will be invited to submit their own questions via text message throughout the proceedings.

Registration:
To register or learn more visit: www.ResearchToPractice.com/Meetings/GynOnc2017 

This activity is supported by Eli Lilly.

ISS VI: Dissecting the Decision: Investigators Discuss Available and Emerging Data Shaping the Role of PARP Inhibition in the Management of Ovarian Cancer

Tuesday, March 14
12:45 p.m. – 2:15 p.m.
Maryland AC
(Part 2 of a 2-Part Series)
CME: 1.5 AMA PRA Category 1 Credits™ provided by Research To Practice.

Course Director:
Neil Love, MD, Research to Practice

Faculty:
Robert Coleman, MD, The University of Texas MD Anderson Cancer Center,
Houston, TX
Jonathan Ledermann, MD, Cancer Research UK and University College London
Cancer Trials Centre, London, England
Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA
Richard T. Penson, MD, MRCP, Harvard Medical School, Massachusetts General Hospital

This symposium will focus on the discussion of actual patients with ovarian cancer treated within the practices of the clinical investigator faculty members. All patients featured will have either been treated or considered for treatment with an approved or investigational PARP inhibitor. By structuring the program around real patients, Research to Practice aims to create a dynamic educational offering designed to improve clinicians’ knowledge and assist them in becoming better and more effective caregivers. During each of the live event’s topic modules, one of the faculty members will deliver a brief presentation reviewing recent findings, current management approaches and ongoing research that informs their decision-making for the specific scenario(s).

Registration:
To register or learn more visit: www.ResearchToPractice.com/Meetings/GynOnc2017 

This activity is supported by Abbvie Inc, AstraZeneca Pharmaceuticals LP, Myriad Genetic Laboratories and Tesaro Inc.

ISS VII: Advancing Molecular Diagnostics for Gynecologic Cancer: Efforts in Data Sharing and Tumor Testing to Improve Care

Tuesday, March 14
Maryland BD
12:45 p.m. – 2:15 p.m.

Course Director:
Jessica Profato-Partlow, MS, CGC

Faculty:
Mike Janicek, MD, Arizona Oncology, Scottsdale, AZ
Virginia Speare, PhD, CGC

Mike Janicek, MD

Identifying mutations, both germline and somatic, is becoming a key aspect of gynecologic cancer treatment, and knowledge regarding hereditary gynecologic cancer is increasing. This session will review techniques Ambry is using to identify mutations and therapeutic targets. We will also review data from recent research in this area and highlight the importance of data sharing and its role in the advancement of molecular diagnostics for gynecologic cancer. Additionally, paired tumor and germline genetic testing is becoming increasingly relevant for guiding diagnosis, treatment, and future care of patients with gynecologic malignancies. This session will outline some examples of this, such as the potential importance of utilizing paired tumor and germline testing when pursuing genetic testing for Lynch syndrome.

This activity is supported by Ambry Genetics.

SGO does not offer CME/CE for any of the ISS. The offering of ISS does not constitute endorsement by the SGO of the information, products or services contained therein. Registration for all symposia starts 30 minutes before the scheduled times.